Oral THC produced psychoactive effects comparable to smoking marijuana in chronic pain patients
In chronic pain patients on opioids, oral dronabinol at 10 and 20 mg produced psychoactive effects similar in peak intensity to smoking low and high strength marijuana cigarettes, respectively.
Quick Facts
What This Study Found
In a randomized controlled trial with 30 chronic non-cancer pain patients on opioids, single doses of dronabinol (10 mg and 20 mg) produced significantly elevated scores on four of five psychoactivity subscales compared to placebo. Peak psychoactive effects at 2 hours after oral dosing were comparable to peak effects at 30 minutes after smoking marijuana.
The 10 mg dose produced effects similar to a low-strength (1.99% THC) marijuana cigarette, while 20 mg matched a high-strength (3.51% THC) cigarette. Importantly, daily morphine use, total pain relief, age, sex, and baseline pain level did not significantly affect the psychoactive profile.
Key Numbers
30 pain patients. 10 mg and 20 mg dronabinol elevated 4/5 ARCI subscales vs. placebo (P < 0.05). Peak effects at 2 hours comparable to smoked marijuana peak at 30 minutes (P = 0.80). Comparison: 10 mg matched low-strength, 20 mg matched high-strength marijuana.
How They Did This
Randomized controlled trial with single doses of placebo, 10 mg, or 20 mg dronabinol in 30 chronic pain patients taking opioids and not using marijuana. Psychoactive effects measured hourly for 8 hours using the Addiction Research Center Inventory (ARCI). A comparison sample of 20 pain-free individuals who smoked marijuana provided reference values.
Why This Research Matters
As cannabinoid medications are prescribed more widely for pain, understanding their psychoactive profile is essential. These data show that oral dronabinol produces meaningful psychoactive effects that must be weighed against its analgesic benefits.
The Bigger Picture
When cannabinoids are prescribed for pain, the psychoactive effects are not just side effects but potential risks for driving, work, and daily functioning. Knowing that a 20 mg dose of oral THC produces effects equivalent to smoking marijuana helps patients and clinicians make informed decisions.
What This Study Doesn't Tell Us
Small sample of 30 patients. Single-dose design may not reflect chronic dosing. Comparison to smoked marijuana was made using a separate group of pain-free individuals, not within-subject. The marijuana comparison cigarettes (1.99% and 3.51% THC) are much weaker than modern cannabis.
Questions This Raises
- ?Do psychoactive effects diminish with repeated dosing (tolerance)?
- ?How do the psychoactive effects compare to the analgesic benefits for individual patients?
- ?Would modern-potency cannabis produce stronger effects than the low-potency comparison cigarettes used?
Trust & Context
- Key Stat:
- Oral THC peak psychoactive effects were comparable to smoking marijuana
- Evidence Grade:
- Randomized controlled trial with validated psychoactivity measures, though small sample and between-group comparison for marijuana reference.
- Study Age:
- Published in 2014. The comparison marijuana cigarettes (1.99-3.51% THC) are much weaker than typical modern cannabis.
- Original Title:
- The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.
- Published In:
- The Clinical journal of pain, 30(6), 472-8 (2014)
- Authors:
- Issa, Mohammed A, Narang, Sanjeet, Jamison, Robert N, Michna, Edward, Edwards, Robert R, Penetar, David M, Wasan, Ajay D
- Database ID:
- RTHC-00809
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does oral THC (dronabinol) get you high?
Yes. In this study, both 10 mg and 20 mg doses produced significant psychoactive effects comparable to smoking marijuana, though the onset was slower (peak at 2 hours vs. 30 minutes for smoking).
How do dronabinol psychoactive effects compare to smoking?
Peak effects were statistically equivalent: 10 mg oral matched low-strength marijuana, 20 mg matched high-strength marijuana. The key difference was timing: oral peaked at 2 hours, smoking at 30 minutes.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00809APA
Issa, Mohammed A; Narang, Sanjeet; Jamison, Robert N; Michna, Edward; Edwards, Robert R; Penetar, David M; Wasan, Ajay D. (2014). The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.. The Clinical journal of pain, 30(6), 472-8. https://doi.org/10.1097/AJP.0000000000000022
MLA
Issa, Mohammed A, et al. "The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.." The Clinical journal of pain, 2014. https://doi.org/10.1097/AJP.0000000000000022
RethinkTHC
RethinkTHC Research Database. "The subjective psychoactive effects of oral dronabinol studi..." RTHC-00809. Retrieved from https://rethinkthc.com/research/issa-2014-the-subjective-psychoactive-effects
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.